PHARMACOLOGICAL PROFILE OF THE NOVEL POTENT ANTIRHEUMATIC ',4'-DIFLUOROBIPHENYL-4-YL)-2-METHYL-4-OXOBUTANOIC ACID

On the basis of basic screening for novel, more potent antiarthritics VUFB-16066 ',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid, CA S 112344-52-2) was chosen as a compound with pronounced anti-inflammat ory and immunomodulatory effects, with good gastric tolerance and rela tively low toxicity. VUFB-16066 Is a dual cyclooxygenase and 5-lipoxyg enase inhibitor, and it suppresses alloantigen-driven cellular immune response and phagocytosis of stimulated peritoneal cells. VUFB-16066 e xhibits prolonged pharmacological activity connected with its major me tabolite having a very long half-life. In the model of adjuvant arthri tis VUFB-16066 improves most of disease symptoms including immunopatho logical disturbances, which indicates possible disease-modifying activ ity of the drug. The beneficial antiarthritic effect of VUFB-16066 has been also confirmed in patients with rheumatoid arthritis.